Mainz Biomed NV, a molecular genetics diagnostic company, announced the pricing of a $4.0 million follow-on offering of 2,000,000 units, each consisting of an ordinary share and Series A and B warrants. The units are priced at $2.00 each. The Series A and B warrants are exercisable at $2.00 per share, with the Series A warrants expiring five years from issuance and Series B warrants expiring either 30 days after eAArly Detect 2 study results or one year from issuance. Additionally, a Warrant Amendment Agreement reduces the strike prices of previously issued warrants to $2.00. Maxim Group LLC is the sole placement agent, with the offering expected to close around May 21, 2025.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。